Fibromyalgia

Almost 50% of fibromyalgia patients use cannabis for symptom relief, according to new study. Experts suggest results underline need for clinician awareness, further research.

EULAR’s fibromyalgia guidelines provide comprehensive recommendations for managing active fibromyalgia to assist clinicians in making informed decisions. Test your knowledge with this quiz.

Without controlling for the severity of symptoms, patients with either fibromyalgia or RA performed worse when compared with controls in terms of cognitive domains including verbal memory, visual memory, and strategic planning.

Results offer important guidance for healthcare providers to develop tailored treatment strategies that align with the unique needs and preferences of individual patients.

Gut microbiota-based treatment relieved pain for patients with fibromyalgia.

Of 1156 participants with chronic musculoskeletal pain, 1073 participants retired at an earlier age. Participants with chronic pain were 1.25 times more likely to stop working.

Aquatic therapy for women with fibromyalgia in Spain is better than land-based therapy for reducing pain levels and improving sleep quality, as seen at the 6-week follow-up.

The overall effect of psychological interventions on patients with fibromyalgia was -0.31 for depressive symptoms and -0.15 for anxiety symptoms, which were deemed statistically significant.

The rheumatology month in review highlights cognitive dysfunction in patients with fibromyalgia, explores the impact of obesity on treatment response in rheumatoid arthritis, and evaluates work-related challenges faced by patients with psoriatic arthritis.

A progressive and significant increase in the frequency of strong opioid consumers was observed over a 12-year period, increasing from 5.8% to 12.8%.

Patients with fibromyalgia and cognitive dysfunction report feeling a loss of identify and impaired social interaction.

Fibromyalgia poses challenges extending beyond physical symptoms due to societal misconceptions and inadequate understanding. Clinicians emphasize the importance of addressing mental health, engaging patients actively, and creating supportive environments to improve the wellbeing of these patients.

Patients with fibromyalgia have poorer accuracy for divided attention, mediated by sleep disturbance, according to a new study.

The rheumatology month in review highlights the challenges of fibromyalgia management and uncovers compelling associations regarding rheumatic disease and comorbidities.

Lora Black, PhD, sheds light on the importance of patient-centered education and comprehensive care in fibromyalgia.

The presence of mental health, pain-related illnesses, and metabolic diseases were significantly associated with the worsening of arthritis-related pain, severity, and disease activity.

Findings shed light on the potential significance of recognizing and managing type D personality traits in the context of fibromyalgia care.

Thematic analysis revealed common themes, including uncertainty about the cause of fibromyalgia, feelings of invisibility, confusion about symptoms and flares, and a strong desire for more accessible treatment information.

Only 10% of providers surveyed follow the American College of Rheumatology criteria for fibromyalgia.

Results indicate the potential relevance of pressure pain thresholds for understanding the mechanisms that contribute to pain in fibromyalgia.

The rheumatology month in review highlights fibromyalgia complexities, lupus advancements, and dietary links to gout for improved management.

Among the fibromyalgia studies conducted in the US and Canada over the past 22 years, 90% of participants identified as White.

Philip J. Mease, MD, highlights the potential of blood biomarkers to assist with diagnosing fibromyalgia, as well as other imaging modalities.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

An expert rheumatologist reviews the efficacy and safety of the 3 FDA-approved therapies for treating fibromyalgia—pregabalin, duloxetine, and milnacipran.

Philip J. Mease, MD, comments on the importance of education about fibromyalgia, especially regarding the stigma and the psychological impact of the disease.

Philip J. Mease, MD, provides an overview of fibromyalgia as a primary disorder of central pain processing and modulation.

Dr Daniel J. Clauw shares clinical pearls for the treatment of patients with fibromyalgia and comments on future developments in the pipeline for disease management.

Daniel J. Clauw, MD, shares his approach to selecting FDA approved therapeutic agents for fibromyalgia treatment and his clinical treatment strategy when first-line pharmacological therapy fails.